Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures-Reference-Cited by-同舟云学术

Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures

Published:2023-03 Issue: Volume:32 Page:158-163
ISSN:2213-7165
Container-title:Journal of Global Antimicrobial Resistance
language:en
Short-container-title:Journal of Global Antimicrobial Resistance

Author:

Gagliardini Roberta^ORCID,Lorenzini Patrizia,Cozzi-Lepri Alessandro,Tavelli Alessandro^ORCID,Borghi Vanni,Galli Laura,Tagliaferri Gianmarco,Maggiolo Franco^ORCID,Mussini Cristina,Castagna Antonella,Monforte Antonella d'Arminio^ORCID,Antinori Andrea

Funder

Gilead Sciences

Publisher

Elsevier BV

Subject

Microbiology (medical),Immunology,Immunology and Allergy,Microbiology

Reference25 articles.

1. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs. continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with Human Immunodeficiency Virus type 1: phase;Van Wyk;Clin Infect Dis,2020

2. Dolutegravir plus lamivudine maintains Human Immunodeficiency Virus-1 suppression through week 48 in a pilot randomized trial;Taiwo;Clin Infect Dis,2018

3. Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis;Wandeler;F1000Research,2019

4. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients;Maggiolo;BMC Infect Dis,2017

5. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients;Galizzi;Int J Antimicrob Agents,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care;HIV/AIDS - Research and Palliative Care;2024-04

2. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort;International Journal of Antimicrobial Agents;2024-01

3. Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study;Journal of Antimicrobial Chemotherapy;2023-06-13